ACIP review of the hepatitis B birth dose vaccination remains a grave concern - Please read more here.

Site Search

You searched for "hepatitis D"

  • HBV Journal Review April 2015

    HBF is pleased to connect our blog readers to Christine Kukka’s monthly HBV Journal Review that she writes for the HBV Advocate. The journal presents the
 latest in hepatitis B research, treatment, and prevention from recent academic and medical journals. This month, the following topics are explored: Half of Patients with HBV Genotype C Will Lose HBsAg Five-year Study Shows Tenofovir Dramatically Improves Cirrhosis Tenofovir Also Effective Against Adefovir and Multi-drug Resistance Tenofovir Is Effective in Pregnant Women Who Have Resistance to Other Drugs Estimates of Liver Cirrhosis in the U.S. Jump 50% Taking Antivirals for Three Years After Undetectable Viral Load Reduces Relapse Risk Study Finds Antivirals Can Replace Costly HBIG after Liver Transplant Surgery Hospitalized Hepatitis B Patients Have Higher Death Rates and Longer Stays Than Hepatitis C Patients Small Study Finds Psoriasis Treatment May Not Reactivate Hepatitis B Emulsion Made from Ginkgo Leaves Shows Promise Against Hepatitis B Experimental Treatment Boosts the Immune System and Slows Viral Replication HIV-HBV Coinfected Patients Have High Rates of Hip Fractures April 1, 2015 Volume 12, No 4 by Christine M. Kukka Half of Patients with HBV Genotype C Will Lose HBsAg Researchers predict half of people infected with genotype C of the hepatitis B virus (HBV) will clear the hepatitis B surface antigen (HBsAg) over their lifetimes. This strain of HBV is found primarily in Asia and among Asian-Americans. Clearing HBsAg reduces a patient's risk of liver damage and cancer. In this study, researchers followed 2,121 patients between the ages of 28 and 75 who tested negative for the hepatitis B "e" antigen (HBeAg). Based on the 338 patients who cleared HBsAg over the course of the study, researchers predicted that 56.4% of patients with genotype C would lose HBsAg over their lifetimes, compared to patients with genotype B, who had a 45.7% lifetime clearance rate. In addition to having genotype C,

    http://www.hepb.org/blog/hbv-journal-review-april-2015/
  • Slaying the Fibrolamellar Beast

    … central repository. Donate medical information to the FHC registry. The combined information from shared medical records can be used to learn more about the causes of FHC and how to treat it. At this time, theFibrolamellar Registry is developing the capability/database to serve this purpose.   Why is research so important? Scientists still need to learn more about the genetic changes that cause FHC, and they are getting closer to finding some of the answers. Recently a research group identified a genetic alteration that may cause tumor growth in people with FHC. This is encouraging progress, but we still need to do so much more to find the best treatments or a cure. Currently, there is no single institution or research group collecting information on different treatments for FHC. This lack of knowledge is holding back the progress in fighting this disease. We need to build on the momentum generated by the recent discoveries and continue vital research efforts. Editor’s Note: Join Us on the Hill! The Hepatitis B Foundation (and its dedicated liver cancer program, Liver Cancer Connect) is a member of the Deadliest Cancers Coalition. Along with our coalition partners, we are urging Congress to safeguard funding for cancer research. Please join us on Tuesday, March 10, from 10 -11:30 am in 122 Cannon House Office Building for a congressional briefing on the importance of cancer research.  

    http://www.hepb.org/blog/slaying-the-fibrolammellar-beast/
  • WHO's New HBV Guidelines to Help Combat Africa's Growing Hepatitis B Crisis

    The World Health Organization (WHO) will release their first management guidelines for hepatitis B virus (HBV) by the end of 2014. For the first time, the guidelines will be geared towards resource-constrained countries, where the disease burden is high but resources are lacking. The new guidelines will be particularly welcome in African nations, where the incidence of viral hepatitis is increasing. The overall scope of the World Health Organization's new management guidelines for hepatitis B will include prevention, screening, and treatment of chronic hepatitis B and will be geared towards resource-constrained countries. Thus, WHO’s guidelines will be valuable for countries where the disease burden is high but resources are lacking. The WHO Global Hepatitis Programme established a Guideline Development Group of external experts in 2013, which includes Hepatitis B Foundation (HBF) executive director Joan Block, and is co-chaired by Dr. Brian McMahon, who also serves on the HBF Scientific and Medical Advisory Board. The new WHO guidelines will be particularly welcome news to African nations, where the incidence of viral hepatitis is increasing. According to the WHO Global Hepatitis Survey 2013, the prevalence of chronic hepatitis B virus (HBV) infection on the African continent is up to 8% of the general population, and 75% of the population may have had prior exposure to the virus. Yet, only two of the African member states that responded to the WHO Survey have a written national strategy to prevent and control viral hepatitis. In Ghana, where the incidence of viral hepatitis is increasing, the sero-prevalence rate is high among blood donors (6.7%), pregnant women (6.5%) and school aged children (15.6%), according to Mr. Theobald Owusu-Ansah, president of the Theobald Hepatitis B Foundation and the Hepatitis B Coalition in Ghana. Compounding the lack of public health plans and national investment are factors common in many low-resource countries:

    http://www.hepb.org/blog/whos-new-hbv-guidelines-to-help-combat-africas-growing-hbv-crisis/
  • HBV Journal Review - October 2014

    HBF is pleased to connect our blog readers to Christine Kukka’s monthly HBV Journal Review that she writes for the HBV Advocate. The journal presents the
 latest in hepatitis B research, treatment, and prevention from recent academic and medical journals. This month, the following topics are explored: Chronic Hepatitis B Remains Public Health Challenge in U.S. Epidemiologists Become Molecular Detectives to Investigate HBV Outbreaks Telbivudine Effectively Prevents Infection of Newborns Born to Infected Mothers GGT Blood Test Reveals Fibrosis and Cirrhosis in Hepatitis B Patients Early Research Combining Antivirals with a Protein "De-activator" Shows Promise Diabetes Dramatically Increases Liver Cancer Risk in Cirrhotic Patients Tenofovir Linked to Higher Rates of Bone Loss than Entecavir Tenofovir Equally Effective against Hepatitis B in Asians and Non-Asians Liver Cancer Risk Factors Do Vary Between Racial Groups Even Liver Specialists Fail to Screen Chemotherapy Patients for Hepatitis B European Study Confirms Coffee Dramatically Lowers Liver Cancer Risk HBV Journal Review October 1, 2014 Volume 11, Issue 10 by Christine M. Kukka Chronic Hepatitis B Remains Public Health Challenge in U.S. A new U.S. Centers for Disease Control and Prevention report on hepatitis B prevalence finds that while new infections have declined markedly, treating chronic hepatitis B infection remains a public health challenge. New hepatitis B virus (HBV) infections have plummeted since 1990 due to comprehensive immunizations. The CDC report estimates only 18,760 people were infected with HBV in 2012. In 2012, the highest rates of new infections were among those aged 30–39 years (2.17 cases per 100,000 population), and the lowest were among children under age 19 who had been immunized at birth. Many of the new infections were transmitted sexually or through injecting drug use. However, an estimated 700,000 to 1.4 million U.S. residents are chronically infected. According to the

    http://www.hepb.org/blog/hbv-journal-review-october-2014/
  • HBV Journal Review - July 2014

    HBF is pleased to connect our blog readers to Christine Kukka’s monthly HBV Journal Review that she writes for the HBV Advocate. The journal presents the
 latest in hepatitis B research, treatment, and prevention from recent academic and medical journals. This month, the following topics are explored: Ground-Breaking Study Finds Antiviral Treatment Does Reduce Cancer Risk Sequential Treatment of Antivirals Followed by Interferon Spurs HBeAg Seroconversio Is the Current Recommended Dose of Entecavir Too Low for Some Patients? Measuring Liver Stiffness, Spleen Size and Platelets Can Predict Cancer Risk Tenofovir Effective in Patients with Lamivudine Resistance Entecavir and Adefovir Combo Works Best in Lamivudine-Resistant Patients When Is It Safe to Stop Antivirals? Experts Still Not Sure Liver Stiffness Test Identifies Which Patients Develop Liver Damage After Treatment Stops Study Suggest Hepatitis B Immunization Could Cut Diabetes Risk by Half Herbal Medication Treatment Linked to Liver Failure in Patient with Hepatitis B HBV Journal Review July 1, 2014 Volume 11, Issue 7 by Christine M. Kukka Ground-Breaking Study Finds Antiviral Treatment Does Reduce Cancer Risk For the first time, an authoritative study has found that antiviral treatment appears to reduce the risk of hepatitis B virus (HBV)-related liver cancer. Even though treated patients had more liver damage, their cancer rates were similar to untreated, healthier patients. Researchers from the U.S. Centers for Disease Control and Prevention examined the health records of 2,671 hepatitis B patients treated at four health centers across the U.S. between 1992 and 2011. Half of the patients were Asian-American and about 31% (820) had been treated with antivirals. The treated patients tended to have more liver damage, were older, male and less likely to be Asian-American than untreated patients in the study. Researchers, reporting in the June issue of the journal ofClinical Gastroenterology and

    http://www.hepb.org/blog/hbv-journal-review-july-2014/